Skip to content

Delavirdine

    Brands

    DEA Class; Rx

    Common Brand Names; Rescriptor

    • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)s

    Non-nucleoside reverse transcriptase inhibitor (NNRTI)
    Used with other antiretroviral drugs to treat HIV infection in patients 16 years and older
    May cause drug-induced rashes

    Indicated for the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents.

    Unplanned antiretroviral therapy interruption may be necessary in specific situations, such as serious drug toxicity, intercurrent illness or surgery precluding oral intake (e.g., gastroenteritis or pancreatitis), severe hyperemesis gravidarum unresponsive to antiemetics, or drug non-availability.

    • angioedema
    • Stevens-Johnson syndrome
    • erythema multiforme
    • hepatic failure
    • hemolytic anemia
    • rhabdomyolysis
    • renal failure
    • vasculitis 
    • GI bleeding
    • cardiomyopathy 
    • pancreatitis 
    • muscle paralysis
    • laryngospasm
    • pancytopenia 
    • hyperkalemia 
    • epididymitis 

    —

    Antiretroviral prophylaxis should be provided to all women during pregnancy, regardless of HIV RNA concentrations or CD4 cell count.

    Adults

    1200 mg/day PO.

    Elderly

    1200 mg/day PO.

    Adolescents

    >= 16 years: 1200 mg/day PO.
    < 16 years: Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established.

    Infants

    Safety and efficacy have not been established.

    Delavirdine mesylate

    Rescriptor Oral Tab: 100mg, 200mg